Since many of the clinically relevant DM phenotypes and trajectories are marked by distinct autoantibodies (23), we wondered whether there are additional autoantibody specificities within the anti–TIF1-γ autoantibody–positive subset that might explain those patients in whom cancer either does not emerge, or emerges late. This evidence concerns the gene TRIM33 and dermatomyositis.